File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Current Management of Nasopharyngeal Cancer

TitleCurrent Management of Nasopharyngeal Cancer
Authors
Issue Date2012
Citation
Seminars in Radiation Oncology, 2012, v. 22, n. 3, p. 233-244 How to Cite?
AbstractManagement of nasopharyngeal carcinoma is one of the greatest clinical challenges. Appropriate detection is not easy because of its anatomical location; sensitive biomarkers in addition to endoscopic and radiological examinations would be valuable. One useful biomarker (particularly for nonkeratinizing carcinoma) is the plasma level of Epstein-Barr viral deoxyribonucleic acid, and its role as a tool for prognostication and monitoring disease progress is presented. Radiotherapy is the primary treatment modality, and using radiation therapy in combination with chemotherapy is recommended for the treatment of locoregionally advanced tumors. Intensity-modulated radiotherapy techniques with image guidance to ensure setup precision are recommended if resources allow; adaptive replanning should be considered if major deviations from the intended dose distribution occur during the treatment course. Most contemporary series have reported encouraging results, with locoregional control exceeding 90%; the key problem is distant failure. The therapeutic margin is extremely narrow. Although significant reduction of some toxicities (eg, xerostomia) and better quality of life is now achievable especially for early stages, the risk of major late toxicities remains substantial. This review will focus on the primary treatment: the current consensus and controversies in the treatment strategy for different stages, the choice of chemotherapy regimen, and the key factors for improving the therapeutic ratio of radiotherapy will be discussed. Summary of the current achievement and direction for future improvement will be presented. © 2012 Elsevier Inc.
Persistent Identifierhttp://hdl.handle.net/10722/213966
ISSN
2015 Impact Factor: 3.556
2015 SCImago Journal Rankings: 1.969

 

DC FieldValueLanguage
dc.contributor.authorLee, Anne W M-
dc.contributor.authorLin, Jin C.-
dc.contributor.authorNg, Wai T.-
dc.date.accessioned2015-08-19T13:41:23Z-
dc.date.available2015-08-19T13:41:23Z-
dc.date.issued2012-
dc.identifier.citationSeminars in Radiation Oncology, 2012, v. 22, n. 3, p. 233-244-
dc.identifier.issn1053-4296-
dc.identifier.urihttp://hdl.handle.net/10722/213966-
dc.description.abstractManagement of nasopharyngeal carcinoma is one of the greatest clinical challenges. Appropriate detection is not easy because of its anatomical location; sensitive biomarkers in addition to endoscopic and radiological examinations would be valuable. One useful biomarker (particularly for nonkeratinizing carcinoma) is the plasma level of Epstein-Barr viral deoxyribonucleic acid, and its role as a tool for prognostication and monitoring disease progress is presented. Radiotherapy is the primary treatment modality, and using radiation therapy in combination with chemotherapy is recommended for the treatment of locoregionally advanced tumors. Intensity-modulated radiotherapy techniques with image guidance to ensure setup precision are recommended if resources allow; adaptive replanning should be considered if major deviations from the intended dose distribution occur during the treatment course. Most contemporary series have reported encouraging results, with locoregional control exceeding 90%; the key problem is distant failure. The therapeutic margin is extremely narrow. Although significant reduction of some toxicities (eg, xerostomia) and better quality of life is now achievable especially for early stages, the risk of major late toxicities remains substantial. This review will focus on the primary treatment: the current consensus and controversies in the treatment strategy for different stages, the choice of chemotherapy regimen, and the key factors for improving the therapeutic ratio of radiotherapy will be discussed. Summary of the current achievement and direction for future improvement will be presented. © 2012 Elsevier Inc.-
dc.languageeng-
dc.relation.ispartofSeminars in Radiation Oncology-
dc.titleCurrent Management of Nasopharyngeal Cancer-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.semradonc.2012.03.008-
dc.identifier.pmid22687948-
dc.identifier.scopuseid_2-s2.0-84862127941-
dc.identifier.hkuros265733-
dc.identifier.volume22-
dc.identifier.issue3-
dc.identifier.spage233-
dc.identifier.epage244-
dc.identifier.eissn1532-9461-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats